 Fas Ligand Protein
"Fas Ligand Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A transmembrane protein belonging to the tumor necrosis factor superfamily that was originally discovered on cells of the lymphoid-myeloid lineage, including activated T-LYMPHOCYTES and NATURAL KILLER CELLS. It plays an important role in immune homeostasis and cell-mediated toxicity by binding to the FAS RECEPTOR and triggering APOPTOSIS.
| Descriptor ID |
D053222
|
| MeSH Number(s) |
D12.644.276.374.750.249 D12.776.395.550.312 D12.776.467.374.750.249 D12.776.543.550.312 D23.529.374.750.249
|
| Concept/Terms |
Fas Ligand Protein- Fas Ligand Protein
- CD95L
- Fas Ligand (FasL)
- FasL Protein
- TNF Superfamily, Member 6
- CD178 Antigen
- Antigen, CD178
- Antigens, CD178
- Fas Ligand
- Tumor Necrosis Factor Ligand Superfamily Member 6
- CD178 Antigens
- CD95 Antigen Ligand
- CD95 Ligand
|
Below are MeSH descriptors whose meaning is more general than "Fas Ligand Protein".
Below are MeSH descriptors whose meaning is more specific than "Fas Ligand Protein".
This graph shows the total number of publications written about "Fas Ligand Protein" by people in this website by year, and whether "Fas Ligand Protein" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 | | 1996 | 0 | 1 | 1 | | 1998 | 0 | 3 | 3 | | 1999 | 0 | 5 | 5 | | 2000 | 0 | 3 | 3 | | 2001 | 0 | 2 | 2 | | 2002 | 0 | 3 | 3 | | 2003 | 0 | 2 | 2 | | 2004 | 0 | 7 | 7 | | 2005 | 0 | 2 | 2 | | 2007 | 1 | 0 | 1 | | 2009 | 0 | 1 | 1 | | 2010 | 0 | 1 | 1 | | 2011 | 0 | 2 | 2 | | 2012 | 1 | 1 | 2 | | 2013 | 1 | 1 | 2 | | 2014 | 2 | 0 | 2 | | 2015 | 0 | 1 | 1 | | 2016 | 0 | 2 | 2 | | 2019 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Fas Ligand Protein" by people in Profiles.
-
Yamamoto TN, Lee PH, Vodnala SK, Gurusamy D, Kishton RJ, Yu Z, Eidizadeh A, Eil R, Fioravanti J, Gattinoni L, Kochenderfer JN, Fry TJ, Aksoy BA, Hammerbacher JE, Cruz AC, Siegel RM, Restifo NP, Klebanoff CA. T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy. J Clin Invest. 2019 02 25; 129(4):1551-1565.
-
Lin CM, Plenter RJ, Coulombe M, Gill RG. Interferon Gamma and Contact-dependent Cytotoxicity Are Each Rate Limiting for Natural Killer Cell-Mediated Antibody-dependent Chronic Rejection. Am J Transplant. 2016 11; 16(11):3121-3130.
-
Milanovic D, Pesic V, Loncarevic-Vasiljkovic N, Pavkovic Z, Popic J, Kanazir S, Jevtovic-Todorovic V, Ruzdijic S. The Fas Ligand/Fas Death Receptor Pathways Contribute to Propofol-Induced Apoptosis and Neuroinflammation in the Brain of Neonatal Rats. Neurotox Res. 2016 10; 30(3):434-52.
-
Tufa DM, Ahmad F, Chatterjee D, Ahrenstorf G, Schmidt RE, Jacobs R. IL-1? limits the extent of human 6-sulfo LacNAc dendritic cell (slanDC)-mediated NK cell activation and regulates CD95-induced apoptosis. Cell Mol Immunol. 2017 Dec; 14(12):976-985.
-
Yeruva L, Spencer NE, Saraf MK, Hennings L, Bowlin AK, Cleves MA, Mercer K, Chintapalli SV, Shankar K, Rank RG, Badger TM, Ronis MJ. Formula diet alters small intestine morphology, microbial abundance and reduces VE-cadherin and IL-10 expression in neonatal porcine model. BMC Gastroenterol. 2016 Mar 22; 16:40.
-
Modiano JF, Lindborg BA, McElmurry RT, Lewellen M, Forster CL, Zamora EA, Schaack J, Bellgrau D, O'Brien TD, Tolar J. Mesenchymal stromal cells inhibit murine syngeneic anti-tumor immune responses by attenuating inflammation and reorganizing the tumor microenvironment. Cancer Immunol Immunother. 2015 Nov; 64(11):1449-60.
-
Divan A, Budd RC, Tobin RP, Newell-Rogers MK. ?d T Cells and dendritic cells in refractory Lyme arthritis. J Leukoc Biol. 2015 Apr; 97(4):653-63.
-
Plenter RJ, Grazia TJ, Nelson DP, Zamora MR, Gill RG, Pietra BA. Ectopic expression of Fas Ligand on cardiomyocytes renders cardiac allografts resistant to CD4(+) T-cell mediated rejection. Cell Immunol. 2015 Jan; 293(1):30-3.
-
Kearns MT, Barthel L, Bednarek JM, Yunt ZX, Henson PM, Janssen WJ. Fas ligand-expressing lymphocytes enhance alveolar macrophage apoptosis in the resolution of acute pulmonary inflammation. Am J Physiol Lung Cell Mol Physiol. 2014 Jul 01; 307(1):L62-70.
-
Gump JM, Staskiewicz L, Morgan MJ, Bamberg A, Riches DW, Thorburn A. Autophagy variation within a cell population determines cell fate through selective degradation of Fap-1. Nat Cell Biol. 2014 Jan; 16(1):47-54.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|